Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.
Read More »Adding GLP-1 to Insulin
EASD: SGLT-2/GLP-1 Combo Better Than Monotherapy
Trial finds improvement in control and weight loss.
Read More »Three Patients, Three Solutions
I have had several patients who did well at first with their GLP-1 agonists. Patient 1: Man, 46 years of age, used liraglutide 3mg daily for obesity. Patients 2 & 3: 2 women in their 60s were using liraglutide for type 2 diabetes & weight.
Read More »Semaglutide Beats Dulaglutide in Head-to-Head Trial
Semaglutide trumps Trulicity in most recent trial.
Read More »GLP-1 Agonist Has CV Benefits
New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.
Read More »Using a GLP-1 Agonist to Prevent Type 2
Results determined for 3-year study of liraglutide versus placebo diabetes risk reduction and weight management in individuals with prediabetes.
Read More »GLP-1 Receptor Agonist for Type 1’s
Besides lowering A1c, study finds success with using less insulin and weight reduction.
Read More »Liraglutide Reduces Liver Fat Content in Patients With Poorly Controlled Type 2 Diabetes
A proposed benefit of GLP-1 agonists confirmed in a human study.
Read More »AACE: Complete Reversal of Type 2 Diabetes With GLP-1 Agonist
Retrospective analysis presentation shows liraglutide (LIRA) improved glycemic parameters, reduced body weight, BMI, and waist circumference in new T2 patients.
Read More »Importance of GI Events for GLP-1 Receptor Agonists
Study finds fewer T2 patients on exenatide once-weekly reported gastrointestinal adverse events, compared with those on exenatide twice-daily or liraglutide once-daily.
Read More »